Robust pharmacokinetic analysis for population studies in breast cancer detection using the Mohan-Shinagawa model by Mohan, Vandana et al.
Robust pharmacokinetic analysis for population
studies in Breast Cancer detection using the
Mohan-Shinagawa model
Vandana Mohan1,2, Yoshihisa Shinagawa1, Bing Jian1, and Gerardo Hermosillo
Valadez1
1 Siemens Medical Solutions, Malvern, PA, USA
2 Georgia Institute of Technology, Atlanta, GA, USA
gth115a@mail.gatech.edu
Abstract. The pharmacokinetic (PK) analysis of breast MRI data us-
ing prior methods like the Tofts model-based approaches involved the
estimation of the amount of contrast agent (CA) fed to the tissue, called
the Arterial Input Function (AIF). The Mohan-Shinagawa model (hence-
forth referred to as the M-S model), is a novel expanded model (derived
from the Tofts model) proposed in (1). It analytically eliminated the AIF
from the analysis but required the robust selection of suitable reference
regions across images. In this paper, the authors propose a novel frame-
work for Tofts model estimation, using the M-S model as an intermediate
stage. The advantages are that the AIF estimation is eliminated, and the
final estimated PK parameters are independent of the reference region
selected. This highly simplifies the overall analysis and improves the ro-
bustness in population studies by reducing the bias introduced by the
reference region selection while keeping the advantages of the M-S frame-
work including a reduction in scattered false positives. Also, as compared
to the M-S model, the physical interpretation of the Tofts model param-
eters is well documented (2). This framework could potentially also be
used for analysing DCE-MRI of other anatomical structures.
1 Introduction
The diagnosis of breast cancer from Magnetic Resonance Imaging (MRI) data is
a difficult problem exacerbated by the fact that a malignant lesion often displays
intensity patterns similar to benign tissues and other structures (such as the ves-
sels) in the field of view. However, malignant tissues differ from benign tissues
in how Contrast Agents (CA) flow in and leak out. The CA molecules affect
the observed intensity patterns because they change the longitudinal relaxation
times at the voxels in the image. Malignant tissues display a characteristic pat-
tern with regard to the amount of CA that washes in, and the rates of entry and
washout of the CA. Dynamic Contrast-Enhanced (DCE) MRI uses this kinetic
property to identify regions of interest. PK analysis aims to quantify this washin
and washout of the CA towards differentiating malignant and benign lesions.
PK analysis aims to provide a framework where the kinetics of CA within the
tissue of interest can be quantitatively described and compared across data sets
from one or more patients and/or MR systems. However, many current systems
do not meet this requirement due to the limited normalization that the system
can perform on the input image data, which impairs the effectiveness of any
population studies conducted.
Existing models for Pharmacokinetic analysis for breast MR can be categorized
into two broad classes - compartmental and heuristic (3; 4; 5). The first class
describes the microscopic view of the breast tissues as a set of compartments and
models the interaction between these compartments with respect to the entry
and exit of the CA. Heuristic models try to model the washin and washout
phenomena - as growing(/decaying) exponentials for example - and quantify
these characteristics. Of the compartmental models, the Tofts model (2) is the
most commonly used. The M-S model (1) was derived as an attempt to address
the issues in the Tofts model with respect to the normalization over data sets,
and the estimation of the Arterial Input Function (AIF). The approach was
the use of a reference region (RR) concept previously explored in work such
as (6) with the RR as the nipple region (detected by using the work in (7)).
While this RR approach performed well on the population study performed
in (1), it possessed the disadvantage that the RR selection affected the extent
of normalization. This affected its reliablity in population studies. This paper
proposes a framework based on the M-S model which addresses the sensitivity
to RR while keeping the original advantages of the model. The approach is to
estimate the Tofts model parameters from the M-S model parameters. Since this
decorrelates the voxel-wise Tofts model parameters, the framework is in theory
independent of the choice of RR as verified by the results in this paper. At the
same time, by the initial estimation of the M-S model parameters, we retain the
advantage of not needing to estimate or approximate the AIF.
2 The M-S model
2.1 Model
The M-S model describes the concentration of Contrast Agent (CA) at a voxel
under analysis, with respect to that at a reference voxel. The model is given by:
cT (t) = (A1e
−B1t +A2e
−B2t) ∗ cR(t) +A3cR(t) (1)
Here, cT (t) denotes the concentration at the voxel being analysed, and cR(t) de-
notes the concentration at the reference voxel. A1, B1, A2, B2 and A3 denote the
parameters of the M-S model which are functions of the Tofts model parameters
at the two voxels being considered.
To recapitulate the extended Tofts model, the time-behavior of the concentration
of CA at the voxel under analysis and the reference voxel are described as:
cT (t) = vpcp(t) +K
trans
cp(t) ∗ e−kept (2)
cR(t) = v
R
p cp(t) +K
transR
cp(t) ∗ e−k
R
ept (3)
where cp(t) denotes the true AIF, vp, K
trans and kep are the Tofts model pa-
rameters for the voxel being analysed, and vRp , K
transR and kRep are the Tofts
model parameters for the reference voxel. A more detailed explanation can be
found in (2).
From (1), the M-S model parameters are related to the Tofts model parameters
at the two voxels as follows:
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Ktrans
R
vRp (kep − kRep)−KtransR
vp(k
R
epv
R
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transR)− vRp (kepvp +Ktrans)
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R
ep − kep) +KtransR
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vRp
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R
ep +
K
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vRp
and B2 = kep
(4)
2.2 Advantages of the M-S model over Tofts model-based
approaches with standard AIF
Existing pharmacokinetic frameworks that use the extended Tofts model require
the AIF for analysis, and since it is difficult to measure AIF in vivo, it has to be
estimated in a reasonable fashion for the subsequent analysis to be reliable. The
work in (1) has demonstrated that Tofts model estimation with the standard
AIF yields results that are not satisfactory for population studies with the use
of one standard AIF for all subjects reducing the extent of normalization of the
results across patients.
The M-S model (1) utilized the fact that the AIF is by definition the concen-
tration of the CA being fed to the tissue under analysis, and used the concept
of a reference region to relate the concentration of the CA at the voxel under
analysis to that of the reference voxel rather than the AIF. This eliminated the
AIF from the analysis. This further led to the advantage that with the reference
region being selected uniformly across data sets from different subjects, the esti-
mated PK parameters displayed a higher degree of normalization, and localized
the malignant lesions better with reduced false positives. Further, this faciliated
population studies as was indicated by the estimated ROC curves, which indi-
cated that the M-S model yielded better discrimination between malignant and
benign lesions than the Tofts model using the standard AIF.
2.3 Disadvantages of Pharmacokinetic analysis using the M-S
model
The performance of the M-S model in population studies is tied to how reliably
the reference region is selected across different datasets. It was first attempted
to assign a form of reliability score to the choice of reference region to make
it more robust. For example, if the reference region was set to be the nipple
region for a set of analyses, the score would quantify with what probability the
chosen reference region was the nipple region in that data set. However, given
the extent of variablity in the sizes, shapes and intensity distributions of these
anatomical structures across data sets, this score was not simple to formulate.
The alternative is to eliminate the dependency of the performance on the choice
of reference region and this forms the basis for the current work.
3 Proposed framework for Tofts model parameter
estimation
The parameters of the M-S model are functions of the Tofts model parameters for
the two voxels used - the voxel under analysis and the reference voxel. Ideally,
the Tofts model parameters describe the concentration perfectly and can be
assumed to be free of bias in the ideal situation where the exact AIF is known,
and the estimation procedure yields zero error. The M-S model parameters are
functions of these ideal Tofts model parameters. Hence, irrespective of the choice
of reference region, if we could invert the model equations so as to estimate the
Tofts model parameters from those of the M-S model, since all quantities used
are from the available dataset, with ideal error-free estimation, the obtained
values will be the exact Tofts model parameters. Additionally, these now describe
the voxel concentration absolutely and hence the dependence on the choice of
reference region has been eliminated, while retaining the advantage of not having
to estimate the AIF to obtain the Tofts model parameters.
The primary issue in estimating the Tofts model parameters through the M-S
model is that the latter only yields five parameters while in all, there are six
values to be estimated (three each per voxel) for the extended Tofts model.
This implies the need to introduce some form of redundancy (possibly by using
multiple voxels), or to use some additional data.
3.1 Mathematical methodology
The M-S model parameters are related to the parameters of the Tofts model at
the voxel under analysis and the reference voxel as shown by Equation 4.
We can solve these equations to obtain expressions for the various individuals
Tofts model parameters. This simplification yields the following expressions:
vp = A3vp
R
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trans = A2
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(5)
A3k
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2 − kRep(A1 +A2 +A3B1 +A3B2) + (A1B2 +A2B1 +A3B1B2) = 0 (6)
Solving the quadratic equation 6 for kRep, we get the following expression:
k
R
ep =
−b±
√
b2 − 4ac
2a
(7)
a = A3 , b = A1 + A2 +A3B1 +A3B2 and c = A1B2 +A2B1 +A3B1B2
These equations show that taking an inverse of the M-S model yields a quadratic
equation and hence two possible solutions for kRep. Also, the other quantities
can be simplified to ratios with respect to vp
R. This is the highest degree of
simplification possible for this system of equations. The quantities k
trans
vp
and
kep (which can both be determined) are in fact physically significant, however
since our goal is to completely estimate the Tofts model parameters, we still face
the challenge of determining vp
R. This is discussed in the subsequent section.
3.2 Challenges in estimating Tofts model parameters
The quantities vp (or v
R
p ) and k
trans (or ktrans
R
) both multiply terms contain-
ing the AIF in the Tofts model expression. Thus, even with the use of the above
expressions, we can only estimate the quantities of interest as related to vRp .
Since the AIF itself is also unknown at this point, this leaves us with two un-
knowns in the Tofts model expression. Separating out these two quantities is
mathematically intractable, even with techniques like blind deconvolution.
3.3 Framework
The framework is made complete by the fact that the dosage of CA injected
into each patient is known information. By understanding that the AIF is the
concentration of CA fed into the tissue of interest, the implication is that the
maximum value that the AIF can take is the injected dosage density itself. We
can use this observation to compute vRp and thus all Tofts model parameters for
all the voxels under analysis.
We start from the expression for the CA concentration at the reference voxel,
by rewriting it as:
cR(t) = v
R
p cp(t) ∗ (δ(t) +
ktrans
R
vRp
e
−kRept) (8)
Since the quantities kRep and
ktrans
R
vRp
are known, it is possible to use deconvolution
to estimate s(t) = vRp cp(t). This expression was derived to be the following:
s(t) = vRp cp(t) = cR(t)− kRe(kR−k
R
ep)t ∗ cR(t) (9)
kR =
k
transR
vRp
(10)
The theoretical maximum of this signal is vRp D where D is the dosage density
of CA injected into the patient. Thus, to estimate the Tofts model parameters
using Equation 5, we estimate vRp as:
v
R
p =
maxt(s(t))
D
(11)
3.4 Implementation
The implementation of the proposed scheme is two-tiered. The first stage is
the estimation of the M-S model parameters, and the second is the application
of the Equations 5 and 7, coupled with the estimation of vRp using Equation
11 to obtain the Tofts model parameters. The estimation of the M-S model is
discussed in detail in (1). The second stage essentially involves implementing the
Equations 5 and 7. However, there are some associated challenges in practice.
The first challenge in the proposed framework is the estimation of kRep from
the quadratic equation in 6. This is because the M-S model estimate in the
first step is not completely error-free and hence even with the same reference
voxel used throughout the analysis for a given image, the quadratic equations
yielded by the different voxels are not identical. The authors explored multiple
heuristic approaches to this issue. One approach that works well is to weight
highest the kRep values yielded at the voxel with the lowest estimation error.
The second challenge in the framework is that the dosage of CA is required to
estimate vRp . In practice, data sets are encountered where the dosage (per unit
body weight) is not known accurately. To circumvent this issue, the maximum
enhancement in a given image was used as being proportional to the CA dosage.
This yielded satisfactory results in practice and the results in this paper are with
this approach.
4 Experiments, Results and Discussion
The experiments in this work aimed at evaluating the performance of the pro-
posed framework in differentiating malignant lesions from benign by visual in-
spection and in population studies. The proposed framework was applied to a
population of breast DCE-MRI data from 40 patients. The results included are
from the application of the framework to a subset of this data. Also included are
ROC curves comparing the performance of three PK analysis setups which are
Tofts model estimation using the standard AIF, the framework for M-S model
estimation and Tofts model estimation using the framework proposed in this pa-
per with restricted and unrestricted choice of RR, all compared against a manual
segmentation of the ground truth of the lesion. The visualized results in Figure
1 and the ROC comparison in Figure 2 (obtained by QLDA classifers) indicate
that the framework achieves more robust differentiation than direct Tofts es-
timation. The visual comparison with two different choices of RR proves the
hypothesis that the framework is robust to RR selection. Also, as compared to
direct Tofts estimation, the proposed framework leads to more spatially clus-
tered results and less scattered false positives which is desirable especially for
use by radiologists in initial analysis. It is important to note that the current
implementation uses an average value of dosage used per subject since the ab-
solute values of dosage are known but the individual subject body weights are
not known. This is also the same value of dosage as used in the standard AIF
expression. Hence introducing the knowledge of body weights and thus average
dosage per unit of body weight is expected to further improve the classification
accuracy. Also, on closely studying the M-S model parameters estimated for each
choice of RR, it becomes clear that the error in estimation of the M-S model
- which propagates to the final Tofts estimate - is significantly different in the
two cases. This brings into analysis the estimation procedure used - currently
the conjugate gradient method - and the inference is that an alternate choice for
the optimization method that yielded lower error on average, coupled with an
unrestricted choice of RR, would result in improved clasification performance.
5 Conclusions and future work
The proposed framework for Tofts model parameter estimation using the M-S
model, has been implemented and tested successfully on a population of breast
Fig. 1. Results comparing the manually segmented ground truth (Column 1) with
results from direct Tofts Model estimation(Column 2); and the Proposed framework
with restricted RR (Column 3) and unrestricted RR (Column 4). Note the improved
localization of regions of interest, the reduction in false positives, and the improvement
in results afforded by relaxing the restrictions on the RR.
DCE-MRI data from 40 subjects. The physical significance of the estimated pa-
rameters is well documented (2). As compared to direct estimation, the proposed
framework does not use a standard AIF for all subjects and hence displays higher
classification accuracy. The visualization shows that the estimated parameters
display greater spatial clustering and accuracy than direct Tofts estimation. Fur-
ther, it is demonstrated that these estimated parameters are indeed robust to
the selection of reference region. The authors also identified areas of the frame-
work with scope for improving system performance. These are the numerical
optimization method for solving the M-S model, and the quantity used for the
dosage per subject. These are being explored in future work for improving the
framework accuracy in population studies.
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